Drugs

, Volume 64, Supplement 1, pp 27–35 | Cite as

Clinical Experience with Ximelagatran in Orthopaedic Surgery

Review Article

Abstract

Patients who undergo orthopaedic surgery are at substantially increased risk for venous thromboembolic events. These include proximal and distal deep vein thrombosis, with the former more likely to lead to pulmonary embolism and fatal complications. Anticoagulants are routinely used for venous thromboembolism prophylaxis in patients undergoing total hip or total knee replacement surgery. Although current treatments offer effective prophylaxis, they have disadvantages. Warfarin is limited by the requirement for coagulation monitoring to ensure effective and safe use. Similarly, low-molecular-weight heparins (LMWHs) have disadvantages, including the need for parenteral administration. This article brings together data from clinical trials of the novel oral direct thrombin inhibitor, ximelagatran, in the prevention of venous thromboembolism in patients undergoing elective total hip or total knee replacement. The ximelagatran clinical trial programme in orthopaedic surgery has focused primarily on five large multicentre studies in Europe (the Melagatran Thromboprophylaxis in Orthopaedic surgery II and III and Expanded Prophylaxis Evaluation Surgery Study studies) and in the United States (the Exanta Used to Lessen Thrombosis A and B studies), which enrolled more than 8000 patients. In addition, the USA clinical trial programme included three other trials that investigated ximelagatran in orthopaedic surgery; two of these studies focused on prevention of venous thromboembolism after total knee replacement, and one study investigated prevention of venous thromboembolism after total hip replacement. These studies compared ximelagatran with the LMWHs dalteparin and enoxaparin and with warfarin, and were designed to reflect regional differences in venous thromboembolism prophylaxis and to build on findings from previous studies. Generally, ximelagatran has been shown to possess comparable or greater efficacy relative to comparators. The timing and dose of ximelagatran have been shown to be important determinants of its efficacy and safety. As ximelagatran can be given in fixed oral dosing without coagulation monitoring, it is an attractive choice for the prevention of venous thromboembolism in major elective orthopaedic surgery.

Keywords

Warfarin Enoxaparin Venous Thromboembolism Total Knee Replacement Dalteparin 

References

  1. 1.
    Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119(1 Suppl.): 132S–75SPubMedCrossRefGoogle Scholar
  2. 2.
    Paiement GD, Desautels C. Deep vein thrombosis: prophylaxis, diagnosis, and treatment — lessons from orthopaedic studies. Clin Cardiol 1990; 13 (4 Suppl 6.): VI19–22PubMedGoogle Scholar
  3. 3.
    Deitelzweig SB, Vanscoy GJ, Niccolai CS, et al. Venous thromboembolism prevention with LMWHs in medical and orthopaedic surgery patients. Ann Pharmacother 2003; 37 (Pt 3): 402–11PubMedCrossRefGoogle Scholar
  4. 4.
    Fabris F, Luzzatto G, Stefani PM, et al. Heparin-induced thrombocytopenia. Haematologica 2000; 85 (Pt 1): 72–81PubMedGoogle Scholar
  5. 5.
    Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59 (Pt 1): 35–43PubMedGoogle Scholar
  6. 6.
    Eriksson UG, Mandema JW, Karlsson MO, et al. Pharma-cokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clin Pharmacokinet 2003; 42 (Pt 7): 687–701PubMedCrossRefGoogle Scholar
  7. 7.
    Eriksson BI, Arfwidsson AC, Frison L, et al. A doseranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost. 2002; 87 (Pt 2): 231–7PubMedGoogle Scholar
  8. 8.
    Eriksson BI, Bergqvist D, Kalebo P, et al. Melagatran for thrombin inhibition in orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360(9344): 1441–7PubMedCrossRefGoogle Scholar
  9. 9.
    Eriksson BI, Agnelli G, Cohen AT, et al. METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89 (Pt 2): 288–96PubMedGoogle Scholar
  10. 10.
    Dahl O, Eriksson BI, Agnelli G, et al. Influence of time of first dose on the efficacy and safety of postoperative ximelagatran for prevention of thromboembolism after orthopaedic surgery. Pathophysiol Haemost Thromb 2003; 33 (Suppl. 2): 38 [abstract OC068]. Presented at 18th International Congress on Thrombosis, 20–24 June 2004, Ljubljana, SloveniaGoogle Scholar
  11. 11.
    Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490–6PubMedCrossRefGoogle Scholar
  12. 12.
    Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systemic review. Arch Intern Med 2001; 161: 1952–60PubMedCrossRefGoogle Scholar
  13. 13.
    Cohen AT, Agnelli G, Dahl OE, et al. Efficacy and safety of the treatment regimen of melagatran and ximelagatran for prevention of thromboembolic events after total hip or knee replacement: a meta-analysis of 3 randomized, double-blind studies, to evaluate the influence of time and dose [poster]. XIXth Congress of the International Society on Thrombosis and Haemostatsis (ISTH); 2003 July 12–18; Birmingham, UKGoogle Scholar
  14. 14.
    Francis CW, Berkowitz SD, Comp PC, et al. EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349 (Pt 18): 1703–12PubMedCrossRefGoogle Scholar
  15. 15.
    Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002; 137 (Pt 8): 648–55PubMedGoogle Scholar
  16. 16.
    Colwell CW Jr, Berkowitz SD, Comp PC, et al. Randomized double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B [abstract no. 39]. Blood 2003; 102 (Pt 11): 14A, Abs 39Google Scholar
  17. 17.
    Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med 2001; 161 (Pt 18): 2215–21PubMedCrossRefGoogle Scholar
  18. 18.
    Colwell CW Jr, Berkowitz D, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003; 1 (Pt 10): 2119–30PubMedCrossRefGoogle Scholar
  19. 19.
    Schulman S, Wahlander K, Lundstrom T, et al. THRIVE III Investigators. Secondary prevention of venous throm-boembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349 (Pt 18): 1713–21PubMedCrossRefGoogle Scholar
  20. 20.
    Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362(9397): 1691–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of OrthopaedicsSahlgrenska University Hospital/ÖstraGothenburgSweden

Personalised recommendations